No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Robert F. Kennedy Jr. petitioned the FDA to revoke authorization of the shots when they were in high demand and thousands of ...

In this April 16, 2021, file photo, a vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center in the Staten Island borough of New York.

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.